 MPTP Poisoning
"MPTP Poisoning" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A condition caused by the neurotoxin MPTP which causes selective destruction of nigrostriatal dopaminergic neurons. Clinical features include irreversible parkinsonian signs including rigidity and bradykinesia (PARKINSON DISEASE, SECONDARY). MPTP toxicity is also used as an animal model for the study of PARKINSON DISEASE. (Adams et al., Principles of Neurology, 6th ed, p1072; Neurology 1986 Feb;36(2):250-8)
| Descriptor ID |
D020267
|
| MeSH Number(s) |
C10.228.140.079.862.800.300 C10.228.662.600.700.250 C10.720.606 C25.723.705.400
|
| Concept/Terms |
MPTP Poisoning- MPTP Poisoning
- Poisoning, MPTP
- Neurotoxicity Syndrome, MPTP
- MPTP-Induced Parkinsonism
- MPTP Induced Parkinsonism
- Parkinsonism, MPTP-Induced
- Poisoning, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
- MPTP Neurotoxicity Syndrome
- MPTP Neurotoxicity Syndromes
- Neurotoxicity Syndromes, MPTP
|
Below are MeSH descriptors whose meaning is more general than "MPTP Poisoning".
Below are MeSH descriptors whose meaning is more specific than "MPTP Poisoning".
This graph shows the total number of publications written about "MPTP Poisoning" by people in this website by year, and whether "MPTP Poisoning" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 1 | 1 | | 2008 | 0 | 1 | 1 | | 2015 | 1 | 0 | 1 | | 2017 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "MPTP Poisoning" by people in Profiles.
-
Kirkley KS, Popichak KA, Hammond SL, Davies C, Hunt L, Tjalkens RB. Genetic suppression of IKK2/NF-?B in astrocytes inhibits neuroinflammation and reduces neuronal loss in the MPTP-Probenecid model of Parkinson's disease. Neurobiol Dis. 2019 07; 127:193-209.
-
Liang LP, Huang J, Fulton R, Pearson-Smith JN, Day BJ, Patel M. Pre-clinical therapeutic development of a series of metalloporphyrins for Parkinson's disease. Toxicol Appl Pharmacol. 2017 07 01; 326:34-42.
-
Bubak AN, Redmond DE, Elsworth JD, Roth RH, Collier TJ, Bjugstad KB, Blanchard BC, Sladek JR. A potential compensatory role for endogenous striatal tyrosine hydroxylase-positive neurons in a nonhuman primate model of Parkinson's disease. Cell Transplant. 2015; 24(4):673-80.
-
De Miranda BR, Popichak KA, Hammond SL, Miller JA, Safe S, Tjalkens RB. Novel para-phenyl substituted diindolylmethanes protect against MPTP neurotoxicity and suppress glial activation in a mouse model of Parkinson's disease. Toxicol Sci. 2015 Feb; 143(2):360-73.
-
Yu L, Shen HY, Coelho JE, Ara?jo IM, Huang QY, Day YJ, Rebola N, Canas PM, Rapp EK, Ferrara J, Taylor D, M?ller CE, Linden J, Cunha RA, Chen JF. Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann Neurol. 2008 Mar; 63(3):338-46.
-
Liang LP, Huang J, Fulton R, Day BJ, Patel M. An orally active catalytic metalloporphyrin protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in vivo. J Neurosci. 2007 Apr 18; 27(16):4326-33.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|